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Abstract Candida parapsilosis sensu stricto, Candida
orthopsilosis and Candida metapsilosis are human fungal
pathogens with clinical importance. The recently reclas-
sified three closely related species have significant
variation in virulence, clinical prevalence and suscepti-
bility characteristics to different antifungal compounds.
The aim of this study was to investigate the in vitro
activity of atorvastatin and fluvastatin against C. me-
tapsilosis, C. orthopsilosis and C. parapsilosis. Suscep-
tibility tests showed that C. parapsilosis was the most
sensitive while C. orthopsilosis was the least susceptible
species to both drugs. On the basis of the differential
sensitivity, we developed a simple, reliable and highly
cost-effective plate assay to distinguish these closely
related species. Applying this method, 54 isolates
belonging to the C. parapsilosis sensu lato complex
deposited in Szeged Microbial Collection could be sorted
into the three species with 100 % probability.
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Introduction
Molecular studies of the Candida parapsilosis sub-
types recently led to their separation into different,
closely related species: the more prevalent C. par-
apsilosis sensu stricto, Candida orthopsilosis and
Candida metapsilosis [1]. Human diseases caused by
C. parapsilosis complex have significantly increased
in importance and prevalence over the last decade
[2, 3]. Recently, survey data from different hospitals
[4, 5] show that C. parapsilosis sensu stricto is the
second or third most common Candida spp. isolated
from blood cultures. The examination of the distri-
bution of the strains within the C. parapsilosis
complex from different isolates obtained from blood
and other sterile sources in European tertiary-care
hospital revealed that the majority of the isolates (111
of 122) were C. parapsilosis sensu stricto, whereas
significantly fewer (10 of 122) were identified as
C. orthopsilosis and only one isolate was identified as
C. metapsilosis [4]. This has been observed in other
studies [5].
The sensitivity of the three species to antifungal
drugs is different [4, 5], indicating that accurate
identification would influence therapy. Conventional
laboratory methods are unable to differentiate the
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three species, and although molecular methods are
rapid and sensitive, they are not routinely available.
Statins were originally identified as fungal metab-
olites [6] that act as selective inhibitors of the
3-hydroxy-3-methylglutaryl-coenzyme A reductase
[7], which is the enzyme responsible for the conver-
sion of hydroxy-methylglutaryl-coenzyme A into
mevalonic acid. In addition to their cholesterol-
lowering effects, statins possess antifungal activity
through inhibiting the formation of ergosterol, which
is a key component of the cell membrane [8–10]. The
minimal inhibitory concentrations of current statins
against pathogenic fungi and yeasts are rather high;
hence, they are not clinically useful as the required
dose for a therapeutic effect would be associated with
unacceptable serious, toxic side effects. However,
statins can potentially serve to differentiate Candida
species based on susceptibility profiles.
In the present study, the susceptibility of 13 strains
of C. metapsilosis, 20 of C. orthopsilosis and 21 of
C. parapsilosis sensu stricto to atorvastatin and
fluvastatin was examined.
Materials and Methods
Yeast Strains and Cultivation
Strains used in these experiments are listed in Table 1.
They were maintained on YPD (1 % glucose, 1 %
peptone, 0.5 % yeast extract, 2 % agar) medium at
4 C. Clinical isolates originated from Hungarian
hospitals were identified by ITS sequencing in a
previous work [11].
Statins
Atorvastatin (Atoris, KRKA) and fluvastatin (Lescol,
Novartis) were of pharmaceutical grade. Stock solu-
tions were prepared by dissolving the drugs in
methanol and then stored at -80 C. The concentra-
tion of the stock solutions was as follows: atorvastatin
20 mg mL-1, and fluvastatin 40 mg mL-1.
In Vitro Susceptibility Test
The in vitro antimycotic effect of atorvastatin and
fluvastatin was determined by a microdilution method.
The stock solution of statins was diluted in yeast
nitrogen base (YNB) without amino acids (DIFCO)
liquid medium and applied in final concentrations of
50–1.56 lg mL-1 in the case of atorvastatin and
25–0.78 lg mL-1 in the case of fluvastatin. The
experiments were carried out in final volume of
100 lL in 96-well microplates. Yeast nitrogen base
medium was prepared as suggested by the supplier and
contained 1 % glucose as the carbon source. Yeast cell
inoculates were prepared from 2-day-old cultures
cultivated in YPD liquid medium at 30 C with
vigorous shaking. The cells were washed with sterile
distilled water, and after repeated washing, they were
suspended in YNB. The initial cell concentration in
each well was adjusted to 4 9 104 cells mL-1.
The microplate cultures were then grown at 30 C
for 48 h with shaking in a BIOTEK SynergyHT
shaker. Growth was detected by checking the optical
density (OD) of the cultures at 600 nm in every 5 min
(Gen5 software). Non-inoculated medium was used as
background, and the growth control contained inocu-
lated YNB medium (initial cell concentration was
4 9 104 cells mL-1). A growth control containing the
same amount of methanol as the statin-containing
samples was also applied.
The experiments were repeated two times, each
plate carried two parallels per each strain and each
statin.
Plate Assay
Strains cultivated for 48 h at 30 C in YPD medium
were diluted in YNB medium, and 105, 104, 103 and
102 cells were spotted onto YNB plates containing 30,
40 and 50 lg mL-1 fluvastatin or atorvastatin, respec-
tively. The plates were incubated at 30 C for 5 days.
Results and Discussion
The in vitro minimal inhibitory concentration (MIC)
of atorvastatin and fluvastatin against the species of
C. parapsilosis sensu lato complex was studied by
microdilution method. Three strains of each species
were included in the study: C. metapsilosis SZMC
8022, SZMC 1547, SZMC 1548; C. orthopsilosis
SZMC 1545, SZMC 8119, SZMC 8121; and C.
parapsilosis CBS 6318, SZMC 1577, SZMC 8002.
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Table 1 Candida isolates
Species Strain no. Isolation place
1 C. parapsilosis SZMC 1361 Blood, Debrecen, Hungary
2 C. parapsilosis SZMC 1438 Blood, Debrecen, Hungary
3 C. parapsilosis SZMC 8043C Stomach, Pe´cs, Hungary
4 C. parapsilosis SZMC 8045 Blood, Pe´cs, Hungary
5 C. parapsilosis SZMC 1577 Szeged, Hungary
6 C. parapsilosis SZMC 1572 Szeged, Hungary
7 C. parapsilosis SZMC 1568 Szeged, Hungary
8 C. parapsilosis SZMC 8050C Szeged, Hungary
9 C. parapsilosis SZMC 1587 Szeged, Hungary
10 C. parapsilosis SZMC 8051C Szeged, Hungary
11 C. parapsilosis SZMC 1569 Szeged, Hungary
12 C. parapsilosis SZMC 8004 Ear, Debrecen, Hungary
13 C. parapsilosis SZMC 1594 Cannula, Debrecen, Hungary
14 C. parapsilosis SZMC 1590 Urine, Debrecen, Hungary
15 C. parapsilosis SZMC 1592 Sputum, Debrecen, Hungary
16 C. parapsilosis SZMC 8002 Ear, Debrecen, Hungary
17 C. parapsilosis SZMC 1596 Wound, Debrecen, Hungary
18 C. parapsilosis CBS 1954 Olive, Italy
19 C. parapsilosis CBS 6318 Olive
20 C. parapsilosis SZMC 8112 Germany
21 C. parapsilosis SZMC 8113 Sputum, Cagliari, Italy
22 C. metapsilosis SZMC 8029 Blood, Debrecen, Hungary
23 C. metapsilosis SZMC 1547 Unknown
24 C. metapsilosis SZMC 1548 Unknown
25 C. metapsilosis SZMC 8022 Throat, Pe´cs, Hungary
26 C. metapsilosis SZMC 8091 Sputum, Pisa, Italy
27 C. metapsilosis SZMC 8092 Bronchial aspirate, Pisa, Italy
28 C. metapsilosis SZMC 8093 Nail, Pisa, Italy
29 C. metapsilosis SZMC 8094 Feces, Pisa, Italy
30 C. metapsilosis SZMC 8095 Nail, Pisa, Italy
31 C. metapsilosis SZMC 8096 Nail, Pisa, Italy
32 C. metapsilosis SZMC 8097 Feces, Pisa, Italy
33 C. metapsilosis SZMC 8098 Feces, Pisa, Italy
34 C. metapsilosis SZMC 8099 Peripheral blood, Auckland, New Zealand
35 C. orthopsilosis SZMC 1545 Unknown
36 C. orthopsilosis SZMC 1546 Unknown
37 C. orthopsilosis SZMC 8115 Germany
38 C. orthopsilosis SZMC 8116 Germany
39 C. orthopsilosis SZMC 8117 Germany
40 C. orthopsilosis SZMC 8118 Germany
41 C. orthopsilosis SZMC 8119 Germany
42 C. orthopsilosis SZMC 8120 Germany
43 C. orthopsilosis SZMC 8121 Germany
44 C. orthopsilosis SZMC 8122 Germany
45 C. orthopsilosis SZMC 8100 Pisa, Italy, nail
Mycopathologia
123
The applied concentration range was between 50
and 1.56 lg mL-1 for atorvastatin (Fig. 1) and
25–0.78 lg mL-1 for fluvastatin (Fig. 2). The anti-
fungal activity of the atorvastatin varied; C. parapsilosis
was the most sensitive species while the susceptibility of
C. orthopsilosis and C. metapsilosis was similar
(Fig. 1). The MIC100 value (100 % growth inhibition)
of atorvastatin was 25 lg mL-1 for C. parapsilosis
Fig. 1 Growth curves of three representative isolates of C. parapsilosis (a), C. orthopsilosis (b) and C. metapsilosis (c) in the presence
of different concentrations of atorvastatin, measured in 5-min intervals for 66 h
Table 1 continued
Species Strain no. Isolation place
46 C. orthopsilosis SZMC 8101 Pisa, Italy, skin
47 C. orthopsilosis SZMC 8102 L’ Aquila, Italy, catheter
48 C. orthopsilosis SZMC 8103 Pisa, Italy, bronchial aspirate
49 C. orthopsilosis SZMC 8104 Pisa, Italy, nail
50 C. orthopsilosis SZMC 8105 Pisa, Italy, bronchial aspirate
51 C. orthopsilosis SZMC 8106 NCPF, UK, unknown
52 C. orthopsilosis SZMC 8107 Pisa, Italy, skin
53 C. orthopsilosis SZMC 8108 Pisa, Italy, sputum
54 C. orthopsilosis SZMC 8109 Pisa, Italy, catheter
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(Fig. 1a) and 50 lg mL-1 for C. orthopsilosis and C.
metapsilosis (Fig. 1b, c).
Remarkable differences were detected in the sen-
sitivity to fluvastatin: C. parapsilosis was the most
susceptible species, while C. orthopsilosis proved the
less sensitive to it (Fig. 2). Fluvastatin was more
effective than atorvastatin, as it completely inhibited
the growth of C. parapsilosis at 12.5 lg mL-1
concentration (Fig. 2a). C. orthopsilosis was the least
susceptible to fluvastatin (Fig. 2b) as 12.5 lg mL-1
concentration caused only 50 % growth inhibition. In
the case of C. metapsilosis, 90 % inhibition was
demonstrated at this concentration (Fig. 2c).
On the basis of the data presented above, we tested
the sensitivity of our strains of the three species on
solidified YNB medium supplemented with 30, 40 and
50 lg mL-1 fluvastatin or atorvastatin. After 5 days
of incubation at 30 C, none of the 21 strains of
C. parapsilosis sensu stricto could grow on medium
containing the lowest concentration, 30 lg mL-1, of
either fluvastatin or atorvastatin. In contrast, the 20
strains of C. orthopsilosis and the 13 strains of C.
metapsilosis formed colonies at 50 lg mL-1 of ator-
vastatin. At 30 lg mL-1 of fluvastatin, C. orthopsilo-
sis cells grew with inoculates as low as 102 cells
(Fig. 3b), whereas C. metapsilosis colonies were
detected only at the highest cell densities (Fig. 3c).
Hence, fluvastatin at 30 lg mL-1 concentration was
sufficient to discriminate between C. metapsilosis and
C. orthopsilosis using different inoculums of these
species. Based on these results, fluvastatin was
significantly more discriminatory than atorvastatin.
Species differentiation is laborious in the case of
closely related human pathogenic fungi or yeasts.
Several conventional and molecular methods exist,
but all of them have their limits, so new reliable
Fig. 2 Growth curves of three representative isolates of C. parapsilosis (a), C. orthopsilosis (b) and C. metapsilosis (c) in the presence
of different concentrations of fluvastatin, measured in 5-min intervals for 66 h
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approaches are required. Differences in lovastatin
sensitivity have been used for species selection in
Rhizomucor genus in a recent study [12]. Based on
the remarkable difference observed in the suscepti-
bilities of C. parapsilosis, C. orthopsilosis and
C. metapsilosis to fluvastatin, we propose a simple
plate assay to distinguish the strains of the three
species. Our data indicate that a dilution series of the
isolated strain should be inoculated on YNB medium
containing 30 lg mL-1 fluvastatin. C. parapsilosis
strains should not grow under this condition
(Fig. 3a). As C. orthopsilosis is the most resistant
species to this drug, robust growth should occur at
each dilution (Fig. 3b), whereas only the dilutions
with 104 or 105 of C. metapsilosis will have growth
(Fig. 3c). The method was validated with 13 strains
of C. metapsilosis, 20 C. orthopsilosis and 21
C. parapsilosis sensu stricto. In conclusion, this
method provides a simple and effective method for
differentiating these three closely related species,
and this approach can be used as an alternative
technique for definite identification of C. parapsilo-
sis sensu lato isolates, which will be a useful tool for
future epidemiological studies.
Fig. 3 Colony formation of ten representative strains of C. parapsilosis (a), C. orthopsilosis (b) and C. metapsilosis (c) on solid YNB
medium (control) and YNB supplemented with 30 lg mL-1 fluvastatin
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